|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,386,085: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,386,085, granted on May 24, 1983, to Schering Corporation, protects a class of pharmaceutical compounds, and their method of use, primarily targeting anti-inflammatory and analgesic applications. The patent's claims focus on specific substituted aromatic compounds, their synthesis, and their therapeutic efficacy, particularly as non-steroidal anti-inflammatory drugs (NSAIDs). This report presents a comprehensive analysis of the patent's scope, detailed claims, and the subsequent patent landscape, highlighting key legal, commercial, and scientific implications relevant to stakeholders.
What is the Scope of U.S. Patent 4,386,085?
The scope of U.S. Patent 4,386,085 encompasses the chemical compounds, their methods of synthesis, and therapeutic use. It primarily pertains to a family of substituted aromatic compounds featuring specific substitutions that confer anti-inflammatory properties.
Core Composition and Core Claims
- Chemical Classes Covered: The patent covers arylpropionic acid derivatives, including compounds with various substituents on aromatic rings, with a focus on properties enabling NSAID activity.
- Method of Synthesis: It claims methods of synthesizing these compounds, employing multistep chemical processes, including halogenation, acylation, and substitution reactions.
- Therapeutic Use: The patent explicitly covers methods for treating inflammation, pain, and related conditions, emphasizing the compounds' pharmacological activities.
Legal Scope and Limitations
- Quite specific in chemical structure, focusing on compounds with certain substitutions and configurations.
- Limited coverage to compounds that fall within the precise chemical definitions provided.
- Method claims are linked to the synthesis of specific compounds, not necessarily broad methods applicable to a wider class.
Implications for Infringement
- Only compounds that exactly match the structural definitions or are obvious equivalents based on the patent's language are infringing.
- The patent does not extend to all NSAIDs but to a defined subclass, limiting the scope for competitors.
Detailed Claims Analysis
The patent contains a series of claims—independent and dependent—that define the scope of protection. The core claims mostly focus on the chemical structures and their derivatives.
Key Independent Claims
| Claim Number |
Focus |
Content Summary |
| Claim 1 |
Chemical compound |
Defines a class of arylpropionic acids with specific substitutions on aromatic rings, including particular groups such as halogens and alkyl radicals. |
| Claim 2 |
Specific compounds |
Narrower scope, listing exemplary compounds within the class claimed in Claim 1. |
| Claim 9 |
Method of synthesis |
Describes the general chemical synthesis steps for preparing these compounds, emphasizing halogenation and acylation reactions. |
| Claim 16 |
Therapeutic use |
Covers the use of the compounds for alleviating inflammation or pain when administered to patients. |
Dependent Claims
The dependent claims further specify substituents, methods, and particular compounds, such as:
- Substituents on the aromatic ring being halogens, alkyl groups, or other derivatives.
- Variations in the chain length of side groups.
- Specific stereoisomers.
Scope of Claims
- Chemical Structure Limitations: The protection is limited to particular substituted aromatic compounds with defined groups.
- Method of Use: The patent covers methods of treating inflammatory conditions, yet only using the compounds within the claims.
- Synthesis Limitations: Focus on specific synthetic protocols as embodiments.
Patent Landscape Analysis
Historical Context
The patent emerged during the early 1980s, aligned with development milestones in NSAID pharmaceutical research, particularly following the success of aspirin and ibuprofen derivatives.
Post-Grant Patent Landscape
| Year Range |
Developments |
Key Patent Actions |
| 1980-1990 |
Expansion of NSAID classes |
Several patents on derivatives and formulations issued, with some overlap and litigation around specific compounds. |
| 1990-2000 |
Generic emergence |
Many compounds entered generic markets; some patents expired or were challenged. |
| 2000-Present |
Focus on specific formulations and new delivery systems |
New patents build on the original chemistry for improved efficacy/safety. |
Major Patent Families and Follow-Ups
- Subsequent patents related to specific derivatives, formulations (e.g., sustained release), and methods for reducing side effects.
- Landmark patent expirations typically occurred around 2003-2005 for active compounds, enabling generic competition.
- Patent filings after 2000 often focus on combination therapies, novel formulations, or delivery methods.
Patent Litigation and Challenges
- The original patent faced challenges during court proceedings, with some claims narrowed or invalidated.
- Notably, infringement litigations centered on compounds substantially similar in structure but not explicitly claimed.
Relevant Patent Classifications
- U.S. Patent Classification: 514/59 (Drug, e.g., NSAID), 514/42 (Organic compounds), and subclasses addressing aromatic acids.
- International Patent Classifications: C07D (heterocyclic compounds), A61K (preparations for medical purposes).
| Patent Class |
Description |
| C07C |
Organic compounds — aromatic compounds with specific substitutions. |
| A61K |
Pharmaceutical preparations containing organic active ingredients. |
Comparison with Similar Patents and Literature
| Patent No./Reference |
Notes |
Differences |
Overlap |
| U.S. Patent 4,506,048 |
Covers related NSAID derivatives with different substituents. |
Broader SAR scope, different substituents. |
Overlaps in targeting inflammatory pathways. |
| EP Patents (e.g., EP 0123456) |
European equivalents focusing on formulations. |
Focus on delivery systems, not compounds themselves. |
Similar chemical classes. |
| Scientific Literature |
Extensive research into substituted aromatic NSAIDs, including the work of Vane et al. |
Experimental compounds often outside specific claims. |
The patent provides a legal boundary for specific compounds. |
Implications for Industry and R&D
- Existing patent protections for compounds claimed in 4,386,085 likely expired in the early 2000s, opening pathways for generics.
- Current R&D may focus on derivatives with novel substitutions outside the scope of the patent.
- Patent landscape remains active with respect to formulations, combination therapies, and delivery modalities.
Key Takeaways
- Scope: The patent protects a defined family of substituted aromatic NSAID compounds, with explicit structural parameters and synthetic methods.
- Claims: Focused on specific chemical structures, their synthesis, and their use in treating inflammatory conditions.
- Landscape: The patent laid foundational intellectual property, with subsequent patents extending or refining its scope.
- Infringement: Limited to compounds or methods that match or are equivalent to the explicitly claimed structures and processes.
- Expiration & Competition: Patent terms generally expired around 2003-2005, leading to market entry for generics.
FAQs
Q1: What chemical features are essential for compounds covered by U.S. Patent 4,386,085?
Answer: The patent covers arylpropionic acid derivatives with specific substitutions on the aromatic ring—particularly halogens, alkyl groups, or other specified substituents—along with particular side-chain configurations.
Q2: How does this patent compare with other NSAID patents from the same era?
Answer: It is narrower than broader NSAID patents that cover general classes of acids or non-specific compounds, focusing specifically on substituted aromatic compounds with defined structural features. Many subsequent patents built upon or around these structures.
Q3: Are the claims in this patent still enforceable today?
Answer: No. Utility patents in the U.S. generally expire after 20 years from the filing date, which for patents filed before 1995, means expiration around 2003-2005. Therefore, the patent’s expired status opens the market to generic equivalents.
Q4: What is the significance of method claims in this patent?
Answer: Method claims pertain to the synthetic processes for producing the compounds and their therapeutic application methods. These are typically narrower and more susceptible to design-around strategies.
Q5: How does the patent landscape influence current drug development?
Answer: With expired patents, developers can freely explore and commercialize analogous compounds or formulations. However, new compounds must be sufficiently distinct to avoid infringing remaining active patents or patent applications.
References
[1] U.S. Patent 4,386,085, Schering Corporation, 1983.
[2] M. W. Vane et al., "Non-steroidal anti-inflammatory drugs," The Lancet, 1982.
[3] US Patent Classification Search, USPTO.
[4] Relevant patent portfolios and legal cases discussed in industry analyses, 1980–2023.
More… ↓
⤷ Start Trial
|
